SEARCH

SEARCH BY CITATION

References

  • 1
    Swerdlow SH, Nathwani BN, Berger F, et al. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 168-170.
  • 2
    Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005; 23: 6364-6369.
  • 3
    Brody J, Advani R. Treatment of mantle cell lymphoma: current approach and future directions. Crit Rev Oncol Hematol. 2006; 58: 257-265.
  • 4
    Weigert O, Unterhalt M, Hiddeman W, Dreyling M. Current management of mantle cell lymphoma. Drugs. 2007; 67: 1689-1702.
  • 5
    Smith MR. Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol. 2008; 15: 415-421.
  • 6
    Hoster E, Dreyling M, Klapper W, et al;German Low Grade Lymphoma Study Group, European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111: 558-565.
  • 7
    Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23: 7013-7023.
  • 8
    Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma—results of a prospective randomized trial of the European MCL Network. Blood. 2005; 105: 2677-2684.
  • 9
    Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulphan, melphalan, and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. 2007; 86: 101-105.
  • 10
    Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003; 3: 185-197.
  • 11
    Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol. 1996; 14: 1269-1274.
  • 12
    Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002; 69: 11-20.
  • 13
    Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005; 13: 29-38.
  • 14
    Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma [letter]. Blood. 2006; 107: 3407.
  • 15
    Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008; 111: 2385-2387.
  • 16
    Hao S, Sanger W, Onciu M, Lai R, Schlette EJ, Medeiros LJ. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002; 15: 1266-1272.
  • 17
    Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006; 169: 2171-2180.
  • 18
    Romaguera JE, Fayad L, Rodriguez MA, et al. Blastoid mantle cell lymphoma (MCL): 5-yr failure-free survival (FFS) rate of 50%, without failures after 2.5 years following treatment with rituximab (R)-hyperCVAD alternating with R-methotrexate/cytarabine (M/A) [ASH Annual Meeting Abstracts]. Blood. 2006; 108. Abstract 2749.